Yiming Angke-B (01541) submits IMM2510 phase III clinical trial application

Yimingke-B (01541) submitted a phase III clinical trial application of IMM2510 for the treatment of drug-resistant non-small cell lung cancer, and its stock price rose by 6.69%. Guoyuan International Research Report stated that its R&D pipeline is rich and is expected to become a blockbuster drug.

Related stocks

Related News

Changes in Hong Kong stocks | Yi Ming Angke-B soared 8%! Phase III clinical trial application for IMM2510 has been submitted to CDE

智通财经·10月 3, 2025

Changes in Hong Kong stocks | Yi Ming Angke-B soared 8%! Phase III clinical trial application for IMM2510 has been submitted to CDE

Changes in Hong Kong stocks | Yi Ming Angke-B (01541. HK) rose more than 6% and has submitted a phase III clinical trial application for IMM2510 to CDE

智通财经·10月 3, 2025

Changes in Hong Kong stocks | Yi Ming Angke-B (01541. HK) rose more than 6% and has submitted a phase III clinical trial application for IMM2510 to CDE

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/economy/92c4b57cc171fa2e98d252f2e284036e"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://community-service.laohu8.com/v1/financial/theme/news\",params:#themeId:\"92c4b57cc171fa2e98d252f2e284036e\",region:\"SGP\",,,undefined,":{"bottom":false,"list":[{"cardType":"NEWS","cardId":"NEWS.2572572094","cardData":[{"id":"2572572094","pubTimestamp":1759476661,"title":"Changes in Hong Kong stocks | Yi Ming Angke-B soared 8%! Phase III clinical trial application for IMM2510 has been submitted to CDE","summary":"","media":"智通财经","labels":["corporation"],"importantFlag":0,"likeCount":0,"liked":false,"publishNews":true,"publishLive":false,"news_tag":"corporation"}],"position":0},{"cardType":"NEWS","cardId":"NEWS.2572557209","cardData":[{"id":"2572557209","pubTimestamp":1759474903,"title":"Changes in Hong Kong stocks | Yi Ming Angke-B (01541. HK) rose more than 6% and has submitted a phase III clinical trial application for IMM2510 to CDE","summary":"","media":"智通财经","labels":[],"importantFlag":0,"likeCount":0,"liked":false,"publishNews":false,"publishLive":true}],"position":0}],"size":2,"extra":{"requestId":"319bdf2c78c341c7803f4eff5225513c"}},"@#url:\"https://community-service.laohu8.com/v1/theme/info\",params:#region:\"SGP\",,method:\"POST\",data:#themeId:\"92c4b57cc171fa2e98d252f2e284036e\",,,undefined,":{"themeId":"92c4b57cc171fa2e98d252f2e284036e","name":"Yiming Angke-B (01541) submits IMM2510 phase III clinical trial application","description":"Yimingke-B (01541) submitted a phase III clinical trial application of IMM2510 for the treatment of drug-resistant non-small cell lung cancer, and its stock price rose by 6.69%. Guoyuan International Research Report stated that its R&D pipeline is rich and is expected to become a blockbuster drug.","image":"https://static.tigerbbs.com/75893bea54132997d986d37d06d63387","type":2,"style":4,"follow":false,"createTime":1759477546110,"userCounts":0,"rnLink":"https://laohu8.com/RN?name=RNTheme&page=/theme/special/finance&rndata={\"themeId\":92c4b57cc171fa2e98d252f2e284036e}&rnconfig={\"headerBarHidden\": true}","subscribe":false,"allowFollow":false,"hasReward":false,"rewardScore":0,"rewardValidDate":0,"rewardEnd":false,"symbols":["01541"],"tweetCounts":0,"categoryId":"2929bb7468f5415f853fd96fb35d7c3b","options":[],"votedOptionId":"","totalUserCount":0,"followStatus":false,"themeName":"Yiming Angke-B (01541) submits IMM2510 phase III clinical trial application","tweetAmount":0,"imageIsDefault":false}}}